MLI Beyond Daily Injections: Implementing Once-Weekly Basal Insulin to Simplify and Personalize Care
Beyond Daily Injections: Implementing Once-Weekly Basal Insulin to Simplify and Personalize Care is designed for US-based endocrinologists and endocrinology-focused NPs and PAs involved in the management of patients with type 2 diabetes (T2D). Once-weekly basal insulin regimens are poised to enter the treatment armamentarium for diabetes management. Gaps in understanding the unique molecular design and pharmacology of, and latest clinical data on these novel formulations may contribute to therapeutic inertia and delayed implementation of a more convenient, flexible, and potentially safer alternative to daily insulin regimens for patients with T2D.
This interactive Real Answers to Real Questions CME activity will integrate extensive peer-to-peer discussion into didactive presentation elements and provide clinicians with the opportunity to examine the recent scientific advancements related to once-weekly basal insulins and compare their pro and cons with traditional once-daily basal insulin regimens. By tackling real-world, practical questions that endocrinologists and endocrinology-focused NPs and PAs face every day, the activity will prepare these clinicians to confidently integrate once-weekly basal insulins into patient-centered diabetes care when they become available.
Cost: Free
View Offer chevron_rightKey Features
This interactive CME activity explores the science and clinical evidence behind emerging once-weekly basal insulins for T2D. Key features include expert and peer-to-peer discussions, molecular design and pharmacology, comparison with once-daily basal insulin regimens, practical implementation strategies, and patient-centered approaches to overcome therapeutic inertia.
Topics Covered
- Weekly Basal Insulin
- Type 2 Diabetes
Learning Objectives
After completing this activity, the participant should be better able to:
- Differentiate emerging once-weekly basal insulins from traditional once-daily formulations based on molecular structure, mechanism of action, and pharmacokinetic/pharmacodynamic properties
- Interpret the efficacy and safety data of once-weekly basal insulins in late-stage development
- Develop a comprehensive, individualized evidence-based treatment plan for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration
Target Audience
This activity is designed for Endocrinologists and endocrinology-focused NPs and PAs who care for patients with T2D in the United States.
Additional credit info
1.0 AAPA, ABIM MOC, ACCME, ANCC, IPCE
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval if valid until September 17, 2027. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
MIPS
Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Support Statement
This activity is supported by an educational grant from Lilly.